QS Investors LLC grew its holdings in PRA Health Sciences Inc (NASDAQ:PRAH) by 3.8% during the 4th quarter, Holdings Channel reports. The firm owned 65,484 shares of the medical research company’s stock after buying an additional 2,376 shares during the period. QS Investors LLC’s holdings in PRA Health Sciences were worth $5,964,000 at the end of the most recent reporting period.
Several other hedge funds have also added to or reduced their stakes in the company. Caxton Associates LP grew its position in shares of PRA Health Sciences by 79.4% in the fourth quarter. Caxton Associates LP now owns 11,304 shares of the medical research company’s stock valued at $1,029,000 after purchasing an additional 5,004 shares during the last quarter. Advisor Group Inc. grew its position in shares of PRA Health Sciences by 403.6% in the fourth quarter. Advisor Group Inc. now owns 5,384 shares of the medical research company’s stock valued at $490,000 after purchasing an additional 4,315 shares during the last quarter. Quantitative Investment Management LLC acquired a new stake in shares of PRA Health Sciences in the fourth quarter valued at approximately $5,090,000. Fred Alger Management Inc. grew its position in shares of PRA Health Sciences by 17.4% in the fourth quarter. Fred Alger Management Inc. now owns 107,974 shares of the medical research company’s stock valued at $9,833,000 after purchasing an additional 16,027 shares during the last quarter. Finally, Koch Industries Inc. acquired a new stake in shares of PRA Health Sciences in the fourth quarter valued at approximately $1,030,000. Institutional investors and hedge funds own 99.28% of the company’s stock.
Shares of PRA Health Sciences Inc (NASDAQ:PRAH) opened at $92.17 on Wednesday. PRA Health Sciences Inc has a 1 year low of $58.08 and a 1 year high of $95.90. The stock has a market cap of $5,923.63, a P/E ratio of 69.83, a P/E/G ratio of 1.46 and a beta of 0.46. The company has a debt-to-equity ratio of 1.31, a quick ratio of 0.90 and a current ratio of 0.90.
PRA Health Sciences (NASDAQ:PRAH) last announced its earnings results on Wednesday, February 21st. The medical research company reported $1.04 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.02 by $0.02. PRA Health Sciences had a net margin of 3.85% and a return on equity of 22.77%. The firm had revenue of $568.80 million for the quarter, compared to analyst estimates of $543.78 million. During the same quarter last year, the business earned $0.71 earnings per share. PRA Health Sciences’s revenue was up 37.5% compared to the same quarter last year. analysts forecast that PRA Health Sciences Inc will post 3.81 EPS for the current year.
PRAH has been the topic of several research reports. Zacks Investment Research upgraded shares of PRA Health Sciences from a “hold” rating to a “buy” rating and set a $101.00 price target on the stock in a research report on Wednesday, January 17th. Robert W. Baird set a $94.00 price target on shares of PRA Health Sciences and gave the company a “buy” rating in a research report on Friday, December 1st. Mizuho set a $87.00 price target on shares of PRA Health Sciences and gave the company a “buy” rating in a research report on Friday, December 1st. BidaskClub upgraded shares of PRA Health Sciences from a “hold” rating to a “buy” rating in a research report on Thursday, December 14th. Finally, KeyCorp restated a “buy” rating and set a $100.00 target price on shares of PRA Health Sciences in a research report on Wednesday, January 31st. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company. PRA Health Sciences presently has a consensus rating of “Buy” and a consensus target price of $95.67.
In related news, insider David W. Dockhorn sold 72,850 shares of the firm’s stock in a transaction that occurred on Thursday, December 28th. The shares were sold at an average price of $90.83, for a total transaction of $6,616,965.50. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, VP Linda Baddour sold 67,000 shares of the stock in a transaction that occurred on Tuesday, January 16th. The stock was sold at an average price of $90.27, for a total transaction of $6,048,090.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 212,700 shares of company stock worth $19,282,021. 2.10% of the stock is owned by company insiders.
COPYRIGHT VIOLATION NOTICE: “QS Investors LLC Grows Stake in PRA Health Sciences Inc (PRAH)” was published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of U.S. and international copyright and trademark law. The legal version of this piece of content can be viewed at https://ledgergazette.com/2018/03/14/qs-investors-llc-grows-stake-in-pra-health-sciences-inc-prah.html.
PRA Health Sciences Profile
PRA Health Sciences, Inc is a contract research organization. The Company provides outsourced clinical development services to the biotechnology and pharmaceutical industries. The Company offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases.
Want to see what other hedge funds are holding PRAH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PRA Health Sciences Inc (NASDAQ:PRAH).
Receive News & Ratings for PRA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.